Abstract Although kidney injury associated with intravenous bisphosphonate therapy is well documented, there are very few reported instances of oral bisphosphonate therapy leading to focal segmental glomerulosclerosis (FSGS) and kidney failure. We report the case of a 79-yearold woman who developed acute kidney injury due to collapsing FSGS while receiving therapy with weekly oral alendronate therapy for osteoporosis. Withdrawal of alendronate and treatment with corticosteroids resulted in partial recovery of kidney function for a period of 16 months until she developed progressive kidney failure needing long-term dialysis. This case report and the literature review highlight the fact that oral bisphosphonates may be associated with a risk of developing FSGS.
Introduction
Kidney disease associated with bisphosphonate therapy has been well documented since the initial report in 2001 [1] .
In general, this finding has been seen with use of intravenous bisphosphonates in the treatment of malignancy. The kidney pathology has often shown focal segmental glomerulosclerosis (FSGS), or less frequently, acute tubular necrosis (ATN). Recently, case reports of FSGS with oral bisphosphonates have emerged. We present the case of a 79-year-old woman with no known kidney disease who while on treatment with oral alendronate for osteoporosis, developed the collapsing FSGS. After a partial remission with steroid therapy, she progressed to end-stage renal disease (ESRD). This case suggests the advisability of monitoring kidney function and proteinuria while on oral bisphosphonate therapy.
Case report
A 79-year-old woman with a history of hypertension, hyperlipidemia, diastolic heart failure, osteoporosis and hip fracture, presented with bilateral lower and upper extremity edema for 2 months. She also complained of increasing dyspnea on exertion but denied facial swelling, orthopnea or paroxysmal nocturnal dyspnea. At presentation, her blood pressure was 174/65 mmHg, and her physical examination showed distended neck veins and anasarca. The serum creatinine was 2.5 mg/dL compared to 2.0 mg/ dL 1 month prior and 0.9 mg/dL 6 months prior to this admission. Her serum albumin was 1.5 g/dL. Her urinalysis showed high-grade albuminuria, red cells and white cells without cellular casts. Urine albumin to creatinine ratio (ACR) was 17,500 mg/g. She was initially treated for heart failure with high-dose intravenous diuretics and subsequently with aquaresis. After 24 h, her creatinine continued to increase to 3.6 mg/dL, prompting a nephrology consultation. A complete workup for nephrotic syndrome was undertaken, including hepatitis B, C and HIV testing, which were all non-reactive. Her auto immune work up including ANA, anti-DS-DNA, cANCA, pANCA, and cryoglobulins was unrevealing. The urine immunoelectrophoresis was unremarkable but the serum protein electrophoresis revealed a monoclonal protein in the betagamma region measuring 0.62 mg/dL. She subsequently underwent a bone marrow biopsy that showed adequate trilineage cell maturation without any evidence of a myeloma or lymphoma, and she was felt to have MGUS.
A kidney biopsy was performed that showed thirty-one glomeruli. Three glomeruli were globally obsolescent and three (10 %) showed segmental capillary collapse with prominence of visceral epithelial cells (Fig. 1 ) and segmental infiltration of the tuft by foam cells. Focal tubular atrophy and interstitial fibrosis was seen in 10 % of the cortex. The biopsy also revealed focal mononuclear inflammatory cell interstitial infiltrate admixed with neutrophils and eosinophils. Moderate arterial and arteriolar sclerosis was present. Immunofluorescence microscopy showed scattered deposits of IgG, IgA, C3 and C1q. Electron microscopy showed detachment of epithelial cells from underlying basement membrane. Few irregular subepithelial defects and densities were seen along capillary walls. The glomerular basement membrane was irregularly thickened and the mesangium was expanded by an increase in cells and extracellular matrix Based upon these findings, a diagnosis of collapsing FSGS was made. A review of medications from admission included clonidine, torsemide, oxazepam, atenolol, vitamin D, losartan, hydrochlorothiazide, rosuvastatin, levothyroxine and alendronate (70 mg weekly). In view of the absence of other associations, we suspected a possible relationship of the collapsing glomerulopathy to chronic oral alendronate therapy.
Given the findings of collapsing glomerulopathy, the alendronate was stopped immediately and the patient began therapy with oral prednisone. Prednisone was started at a dose of 100 mg every alternate day and was slowly tapered to 40 mg on alternate days over 6 weeks, and she remained on this dose for another 10 weeks. Metolazone was added to torsemide to facilitate diuresis. Over the course of the succeeding months, the patient's ACR decreased dramatically to 2,670 mg/g at 2 months and to 319 mg/g at 12 months after initiating therapy. Her creatinine reduced to 2.0 mg/dL and was stable for a period of 16 months.
Approximately 16 months after the initial admission, the patient presented again with decreasing urine output and worsening anasarca. Her creatinine on admission was 4 mg/dL and her 24 h urine protein had increased significantly to 15 g. She was once again treated with high-dose oral steroids and intravenous diuretics. However, her urine output over the course of the next week decreased significantly despite aggressive diuretic therapy her serum creatinine rose to 10 mg/dL. She started developing signs and symptoms of uremia (tremors, nausea and loss of appetite). A repeat kidney biopsy was considered but not performed as its possible benefits did not justify the risk in the likely setting of progressive collapsing FSGS. A tunneled dialysis catheter was placed and the patient was initiated on hemodialysis. Kidney function stabilized at a measured creatinine clearance of 12-15 ml/min, allowing twice weekly dialysis.
Discussion
The initial report of FSGS secondary to bisphosphonates was in a series of seven patients (six with multiple myeloma and one with breast cancer) who were treated with monthly intravenous pamidronate. Biopsy of all the kidneys showed collapsing FSGS and tubular toxicity [1] . Since then there have been numerous such reports in the [2] [3] [4] [5] . Most often, the kidney injury has been in the setting of intravenous bisphosphonates, primarily pamidronate, used in the treatment of osteolytic bone lesions secondary to cancers, myeloma and hypercalcemia of malignancy [2, 4] .
Prior to our case, four other cases of nephrotic range proteinuria, with or without acute kidney injury (AKI) have been reported in association with oral alendronate use (Table 1) [6] [7] [8] [9] . Three of the four cases were men and all three of the biopsied kidneys showed FSGS. Alendronate was withdrawn in all and three of the four patients received steroids as part of their treatment. Partial or complete remission was reported in all cases. In addition to these reports, Stratton and Warwicker reported two cases of worsening proteinuria with etidronate, another oral bisphosphonate that was used to treat osteoporosis in men with underlying minimal change disease on chronic steroid treatment [10] . In both cases, withdrawal of etidronate resulted in resolution of proteinuria. A major difference between the findings of our study and previously published literature is the lack of temporal association between onset of alendronate therapy and development of FSGS. While proteinuria developed within weeks in other case studies, our patient had been on alendronate for *5 years prior to developing FSGS. However, previous studies of intravenous bisphosphonates have reported the onset of FSGS after 1 year of therapy. It can also be hypothesized that the lower dose of oral bisphosphonate to treat osteoporosis may need a longer period of exposure prior to disease onset.
When bisphosphonate therapy has shown to be associated with nephrotic range proteinuria in previous case reports, the most frequent lesion on pathology has been collapsing FSGS [3, 4, 6] . Although the exact mechanism of renal injury from bisphosphonates is uncertain, podocyte injury seems the most widely accepted hypothesis [11] . In collapsing FSGS, visceral epithelial cells become de-differentiated, enter the cell cycle, lose expression of markers of differentiation and exhibit an immature phenotype [12] . Following this, high-grade proteinuria develops. A similar pattern of injury with loss of podocytes synaptopodin and increased expression of proliferation marker Ki-67 was seen in the initial report of cases of FSGS secondary to pamidronate use [1] .
Bisphosphonates also impair cellular energetic and disrupt cytoskeleton assembly within osteoclasts [13, 14] . Since podocytes have a complex cytoskeletal structure like osteoclasts, a similar effect of bisphosphonates on the podocytes may induce FSGS. The finding that cancer cells undergo a similar apoptosis in the presence of high-dose bisphosphonate is supportive of its effects on other cell types [15] .
Treatment for FSGS is limited and renal outcomes with the collapsing variant are usually poor [16] . In the case of drug-induced secondary FSGS as with bisphosphonates, immediate cessation of the agent may result in reduction in proteinuria. While no controlled studies have reported a definite benefit of corticosteroids, anecdotal evidence suggests that they may help in preserving kidney function. The additional use of rennin-angiotensin-aldosterone system (RAAS) blocking agents to treat hypertension and proteinuria should be considered.
In conclusion, oral bisphosphonates have widespread use in the treatment of osteoporosis. While adverse events including nephrotic syndrome and AKI have been well documented with high-dose intravenous bisphosphonates, a similar association may be emerging with oral agents. The risk is of particular concern in view of the aging population at risk for acute kidney injury. Regular urine dipstick testing for proteinuria in patients on bisphosphonates may be advisable for early detection of podocyte injury.
